CND Life Sciences, Inc. filed an amended Form D with the Securities and Exchange Commission on 2026-06-16.
CND Life Sciences, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on June 16, 2026. The filing reports $6.32M sold. Its industry group is Biotechnology. It names Richard Morello (Executive Officer, Director), Todd Levine (Executive Officer, Director), Peter Harris (Executive Officer, Director) (SEC Form D/A, June 16, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like CND Life Sciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-06-16 · the record
Pitching, partnering or investing alongside them? See who really runs and owns CND Life Sciences, Inc.
Free to see. No signup.
More on the people and the money behind CND Life Sciences, Inc., from the filings we hold.
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when CND Life Sciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when CND Life Sciences, Inc. raises, hires or launches. No email unless you switch it on.
Watch CND Life Sciences, Inc. →Get the full cited report on CND Life Sciences, Inc.
What the filing shows about CND Life Sciences, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on CND Life Sciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives CND Life Sciences, Inc.'s address as 9165 E. Del Camino Drive, Suite 101, Scottsdale, AZ 85258-4381.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for CND Life Sciences, Inc. →
Amended on 2026-08-03: the offering size changed from $6,250,000 to $6,316,514; the amount sold changed from $4,314,750 to $6,316,514; the number of investors changed from 1 to 14. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on CND Life Sciences, Inc. See pricing
CND Life Sciences, Inc. is a registered filer with the SEC (CIK 1841099) and has filed since 2023-07-24. 4 filings are on record, the latest on 2026-06-16.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
CND Life Sciences, Inc.'s Form D of 2026-06-16 names Richard Morello, Todd Levine, Peter Harris and 3 more as its officers, directors or promoters.
Its new offerings report $11.29M sold across 4 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week. The dot is this raise, $6.32M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Checked away from the filing. What is below does not come from the record on sec.gov.
CND advances neurodiagnostics through skin biopsy testing, including the Syn-One Test, for neurodegenerative diseases.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Richard Morello is named as Executive Officer and Director on the Form D that CND Life Sciences, Inc. filed with the SEC on 16 June 2026, one of 6 people that filing names.
Todd Levine is named as Executive Officer and Director on the Form D that CND Life Sciences, Inc. filed with the SEC on 16 June 2026, one of 6 people that filing names.
Peter Harris is named as Executive Officer and Director on the Form D that CND Life Sciences, Inc. filed with the SEC on 16 June 2026, one of 6 people that filing names.
Enrique Carrazana is named as Director on the Form D that CND Life Sciences, Inc. filed with the SEC on 16 June 2026, one of 6 people that filing names.
Christopher Gibbons is named as Director on the Form D that CND Life Sciences, Inc. filed with the SEC on 16 June 2026, one of 6 people that filing names.
Jack Seaver is named as Director on the Form D that CND Life Sciences, Inc. filed with the SEC on 16 June 2026, one of 6 people that filing names.
6 people named on the filing — 3 holding an executive role and 3 as directors only.
Named as of the 2026-06-16 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about CND Life Sciences, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on CND Life Sciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CND Life Sciences, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist CND Life Sciences, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind CND Life Sciences, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-26 (cndlifesciences.com).
Each opens in a new tab, filled in for CND Life Sciences, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Phoenix
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/cnd-life-sciences-inc-form-d-26000001